Abstract 3647
Background
Fixed-dose adjuvant subcutaneous (s.c.) trastuzumab (T) has been approved in the treatment of early HER2-positive breast cancer (BC), based on the evidence of its non-inferiority to standard intravenous (i.v.) infusion. Few data from real-life are available regarding cardiac toxicities associated with fixed-dose subcutaneous T administration. We conducted a retrospective study in order to compare cardiac toxicity profile of adjuvant fixed-dose s.c.-T and weight-based i.v.-T, according to anthropometric data which takes into account more than simply weight.
Methods
Patients treated with adjuvant T for HER2-positive breast cancer at Humanitas Research Hospital from December 2013 to October 2017 were evaluated. T was administered at a either fixed dose of 600 mg s.c. or 6 mg/kg i.v, respectively. Data regarding previous chemotherapy, Body Mass Index (BMI), and development of cardiotoxicity (decrease in LVEF >10% points, to a value < 50%) were extracted from medical records. Four BMI classes were considered: underweight (BMI < 18 kg/sqm), normal weight (18-24.9 kg/sqm), overweight (25-29.99), and obesity (≥30). All variables were compared with categorical tests (Pearson Chi-squared with Yates correction or Fisher exact test).
Results
A total of 260 HER2-positive BC patients receiving adjuvant T were analyzed. Median age was 56 (range, 32-88), median BMI 23.5 (range, 15.8-50.2 kg/sqm). 196 (75.38%) patients received s.c.-T and 64 (24.62%) i.v.-T. 156 had a normal weight, while 11 were underweight, 54 overweight and 39 obese. The incidence of cardiotoxicity was not different among the BMI classes according to the route of administration of T (p = 0.28). In the subset of the patients who had developed cardiac toxicity, BMI did not result as a risk factor, as well as a previous treatment with anthracyclines (p = 0.89).
Conclusions
Cardiac toxicity profile of fixed-dose s.c.-T is consistent with that of weight-based i.v.-T in the real-world setting regardless differences in anthropometric data as BMI. Our study confirms safety of subcutaneous T administration, which still represents a valid and more convenient alternative to intravenous administration.
Clinical trial identification
Legal entity responsible for the study
Istituto Clinico Humanitas.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4596 - Neoadjuvant Trial of nab-paclitaxel and Atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive Triple Negative Breast Cancer (TNBC)
Presenter: Jennifer Litton
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract